Mid-size Biotech
HEOR, Medical Affairs, Epi
Launched
Oncology
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biotech
HEOR, Medical Affairs, Epi
Launched
Oncology
At recent scientific congresses, multiple studies began reporting real-world effectiveness outcomes that appeared to favor a competitor over the client’s treatment.
If left unchallenged, these findings risked reshaping how payers, clinicians, and guidelines interpreted comparative value; despite important differences in study design, patient populations, and endpoints.
The client engaged Alkemi to rapidly assess the emerging evidence, determine what conclusions were supported, and develop a response to protect market position.
1. Designed and facilitated a cross-functional workshop to review emerging congress RWE and clarify decision risk.
2. Evaluated the published and presented RWE to assess methodological rigor, population alignment, and sources of bias.
3. Defined clear evidence-based messages to guide interpretation and external communication.
4. Drafted a targeted abstract reflecting the refined evidence narrative and supported its presentation at a major medical congress to reinforce the client’s position.
Ensure emerging RWE was interpreted in context and used appropriately in decision-making.
"When I presented the project output to our leadership, they said: ‘You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward.’" - Senior Director, Center for Outcomes Research, Real-world Evidence and Epidemiology
Teams gained clarity on what the emerging RWE did, and did not, demonstrate.
The abstract and supporting materials enabled consistent interpretation of the data across scientific and field teams.
By addressing the issue early and publicly, the client reduced downstream access risk and reinforced confidence in the product’s value.